Brett P. Monia Sells 33,445 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) CEO Brett P. Monia sold 33,445 shares of the company's stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $32.63, for a total transaction of $1,091,310.35. Following the sale, the chief executive officer now directly owns 207,396 shares of the company's stock, valued at $6,767,331.48. The trade was a 13.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ionis Pharmaceuticals Stock Down 2.6 %

NASDAQ IONS traded down $0.85 during midday trading on Friday, hitting $31.43. 1,371,506 shares of the company traded hands, compared to its average volume of 1,525,691. Ionis Pharmaceuticals, Inc. has a 52 week low of $31.40 and a 52 week high of $52.49. The company's 50-day simple moving average is $35.63 and its 200-day simple moving average is $41.17. The company has a market cap of $4.96 billion, a PE ratio of -12.88 and a beta of 0.35. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company's stock worth $27,000 after purchasing an additional 303 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in Ionis Pharmaceuticals during the 2nd quarter worth $37,000. Capital Performance Advisors LLP acquired a new position in Ionis Pharmaceuticals during the 3rd quarter valued at about $40,000. Prospera Private Wealth LLC purchased a new stake in Ionis Pharmaceuticals in the third quarter valued at about $42,000. Finally, Quantbot Technologies LP acquired a new stake in Ionis Pharmaceuticals in the third quarter worth about $51,000. Institutional investors own 93.86% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on IONS. William Blair reaffirmed an "outperform" rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Piper Sandler reduced their price objective on Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Royal Bank of Canada reiterated an "outperform" rating and set a $70.00 target price on shares of Ionis Pharmaceuticals in a research report on Wednesday. Needham & Company LLC restated a "buy" rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. Finally, Guggenheim decreased their price objective on Ionis Pharmaceuticals from $70.00 to $65.00 and set a "buy" rating on the stock in a research note on Wednesday, October 9th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Ionis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $60.65.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.